| Epilepsy Behav. 2019 Apr 7;94:195-197. doi: 10.1016/j.yebeh.2019.03.001. [Epub ahead of print]
Safety and tolerability of Vitamin D3 5000 IU/day in epilepsy.
DeGiorgio CM1, Hertling D2, Curtis A2, Murray D2, Markovic D2.
Author information
1Department of Neurology, UCLA School of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA. Electronic address: [email protected] of Neurology, UCLA School of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA.
Abstract
PURPOSE:
Preclinical and early clinical research indicates that Vitamin D3 may reduce seizures in both animal models and open-label clinical trials.
METHODS:
This is an initial report of an ongoing pilot study of oral Vitamin D3 5000 IU/day in subjects with drug-resistant epilepsy. After Institutional Review Board (IRB) approval and informed consent, subjects with ;less than one focal onset or generalized tonic-clonic seizure per month were enrolled. Subjects entered a 4-week baseline, followed by a 12-week treatment period. Serum 25, OH Vitamin D3, Blood Urea Nitrogen (BUN), creatinine, and calcium levels were monitored at baseline and at 6 and 12 weeks.
RESULTS:
High-dose Vitamin D3 5000 IU/day was well tolerated. Serum 25, OH Vitamin D3 levels increased significantly at six and twelve weeks. Vitamin D insufficiency, defined as a 25, OH Vitamin D3 level of <20 ng/ml normalized in all subjects with insufficient vitamin D levels. Median seizure frequency declined from 5.18 seizures per month to 3.64 seizures per month at 6 weeks and to 4.2 seizures per month at 12 weeks. The median percent change in seizure frequency was -26.9% at six weeks, and -10.7% at 12 weeks (not significant, Wilcoxon Signed Rank Test, P > 0.34).
CONCLUSIONS:
High-dose oral Vitamin D3, 5000 IU/day was safe and well tolerated in subjects with epilepsy. Vitamin D levels increased significantly at 6 and 12 weeks but never exceeded potentially toxic levels, defined as >100 ng/ml. To reduce variability, we will now recruit subjects who only have three or more seizures per month.
https://www.ncbi.nlm.nih.gov/pubmed/?term=...day+in+epilepsySafety and tolerability of Vitamin D3 5000 IU/day in epilepsy
Department of Neurology, UCLA School of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA
Abstract
Purpose
Preclinical and early clinical research indicates that Vitamin D3 may reduce seizures in both animal models and open-label clinical trials.
Methods
This is an initial report of an ongoing pilot study of oral Vitamin D3 5000 IU/day in subjects with drug-resistant epilepsy. After Institutional Review Board (IRB) approval and informed consent, subjects with ;less than one focal onset or generalized tonic–clonic seizure per month were enrolled. Subjects entered a 4-week baseline, followed by a 12-week treatment period. Serum 25, OH Vitamin D3, Blood Urea Nitrogen (BUN), creatinine, and calcium levels were monitored at baseline and at 6 and 12 weeks.
Results
High-dose Vitamin D3 5000 IU/day was well tolerated. Serum 25, OH Vitamin D3 levels increased significantly at six and twelve weeks. Vitamin D insufficiency, defined as a 25, OH Vitamin D3 level of <20 ng/ml normalized in all subjects with insufficient vitamin D levels. Median seizure frequency declined from 5.18 seizures per month to 3.64 seizures per month at 6 weeks and to 4.2 seizures per month at 12 weeks. The median percent change in seizure frequency was −26.9% at six weeks, and −10.7% at 12 weeks (not significant, Wilcoxon Signed Rank Test, P > 0.34).
Conclusions
High-dose oral Vitamin D3, 5000 IU/day was safe and well tolerated in subjects with epilepsy. Vitamin D levels increased significantly at 6 and 12 weeks but never exceeded potentially toxic levels, defined as >100 ng/ml. To reduce variability, we will now recruit subjects who only have three or more seizures per month.
https://www.epilepsybehavior.com/article/S...0997-1/fulltext
|
